The results of this study report the role of Pro12Ala polymorphism in PPARγ2 and may provide useful information for the design of Pro12Ala polymorphism-based therapeutic strategies against especially CAD, NAFLD, T2DM, insulin sensitivity, obesity, cardiovascular disease, Alzheimer's disease, and cancer. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.